Aflibercept Biosimilar - Anti-VEGF mAb - Research Grade
Source
DrugBank DB08885
Species
Human
Expression system
Mammalian cells
Molecular weight
115kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Aflibercept,Aflibercept,VEGF,anti-VEGF
Reference
PX-TA1016
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
hG1-Fc
Clonality
Monoclonal Antibody
Description of Aflibercept Biosimilar - Anti-VEGF mAb - Research Grade
General information about Aflibercept
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. This product is for research use only.
Reviews
There are no reviews yet.